European Hematology Association Congress | Conference

First-Line Orelabrutinib Plus FCG Generates Rapid Molecule Remissions in CLL

July 3rd 2024

Orelabrutinib plus FCG led to undetectable MRD in all patients with untreated chronic lymphocytic leukemia who completed 12 cycles of therapy

Liso-cel Shows Improved EFS, PFS, and Durable Responses in Second-line LBCL at 3 Years

June 27th 2024

Liso-cel continued to show improved disease control and EFS and PFS vs SOC in the second-line treatment of patients with large B-cell lymphoma.

TP53 Mutations Are Associated With Unfavorable Prognosis in CLL

June 18th 2024

TP53 mutations have an adverse prognostic role in CLL, regardless of 17p deletion status, in the context of chemoimmunotherapy and targeted agents.

Ide-Cel Generates Durable Responses in Functionally High-Risk Myeloma

June 18th 2024

Ide-cel induced durable responses and had a favorable risk-benefit profile in patients with functionally high-risk multiple myeloma.

Frontline Acalabrutinib/BR Regimen Significantly Improves PFS in Mantle Cell Lymphoma

June 17th 2024

Frontline treatment with acalabrutinib and bendamustine/rituximab (BR) improved PFS over BR alone in older patients with mantle cell lymphoma.

Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL

June 17th 2024

The combination of sonrotoclax and zanubrutinib had a tolerable safety profile and led to durable responses in relapsed/refractory CLL/SLL.

Linvoseltamab Elicits Deep, Durable Responses in R/R Multiple Myeloma

June 17th 2024

Linvoseltamab induced durable responses in patients with relapsed or refractory multiple myeloma, including those with high-risk features.

Prospective Analysis Highlights Patterns of Progression to Myelofibrosis Following Essential Thrombocythemia Diagnosis

June 17th 2024

Patients with essential thrombocythemia who progressed to myelofibrosis had longer duration of disease, higher white blood cell counts, and lower hemoglobin levels at enrollment.

Acalabrutinib and Zanubrutinib Both Best Ibrutinib in Real-World Safety and Efficacy CLL/SLL Outcomes

June 17th 2024

Acalabrutinib and zanubrutinib monotherapy displayed better real-world safety and efficacy in chronic lymphocytic leukemia and small lymphocytic lymphoma compared with ibrutinib.

Lower Tumor Burden Associated With Improved ORR With Liso-Cel in R/R CLL/SLL

June 17th 2024

Lower disease burden improves response to liso-cel treatment in CLL/SLL, reports TRANSCEND CLL 004 trial.

Dr Samarasinghe on the Feasibility of First-Line Blinatumomab in Down Syndrome B-ALL

June 16th 2024

Sujith Samarasinghe, MD, discusses key results from the phase 2 ALLTOGETHER 1 DS trial in Down Syndrome B-cell acute lymphoblastic leukemia.

Dr Trudel on Results From the DREAMM-7 Trial of BVd in R/R Multiple Myeloma

June 16th 2024

Suzanne Trudel, MSc, MD, discusses key results and subgroup analyses from the phase 3 DREAMM-7 trial of BVd in relapsed/refractory multiple myeloma.

Zanubrutinib Associated With Cost Savings and QALY Benefits vs Acalabrutinib in B-Cell Malignancies

June 15th 2024

Zanubrutinib was associated with improved cost savings and quality-adjusted life year benefits vs acalabrutinib in B-cell malignancies.

ATRA/ATO Regimen Improves EFS in Newly Diagnosed, High-risk APL

June 15th 2024

Arsenic trioxide plus all-trans retinoic acid & idarubicin improved EFS vs standard ATRA and anthracycline-based chemotherapy in high-risk APL.

Glofitamab Plus Gemcitabine/Oxaliplatin Shows Survival Benefit in Transplant-Ineligible R/R DLBCL

June 15th 2024

Adding fixed-duration glofitamab-gxbm (Columvi) to gemcitabine and oxaliplatin led to a statistically significant and clinically meaningful improvement in survival vs rituximab (Rituxan) plus gemcitabine/oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplant.

Dr Bertossi on the Prognostic Role of TP53 Mutations in CLL

June 15th 2024

Consuelo Bertossi, MD, discusses the role of TP53 mutations and their prognostic significance in chronic lymphocytic leukemia.

Dr Grunwald on the Rates of Disease Progression in Low-Risk Myelofibrosis

June 15th 2024

Michael R. Grunwald, MD, FACP, discusses disease progression in patients with low-risk myelofibrosis enrolled in the prospective MOST study.

Zanubrutinib Plus Obinutuzumab/Venetoclax Is Safe, Elicits Responses in Older Patients With Untreated MCL

June 15th 2024

The combination of zanubrutinib, obinutuzumab, and venetoclax was safe and well-tolerated in older patients with untreated mantle cell lymphoma.

Earlier Use of Acalabrutinib Associated With Improved Survival in CLL

June 14th 2024

Earlier use of acalabrutinib was associated with improved survival in patients with chronic lymphocytic leukemia.

CAR T-Cell Therapy Is Safe, Feasible in Outpatient Setting for NHL

June 14th 2024

The administration of CAR T-cell therapy in the outpatient setting was deemed feasible and safe in patients with relapsed/refractory NHL.